

Romina Mizrahi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/798147/publications.pdf>

Version: 2024-02-01

143
papers

8,046
citations

44069

48
h-index

53230

85
g-index

147
all docs

147
docs citations

147
times ranked

9570
citing authors

#	ARTICLE	IF	CITATIONS
1	<sc>N400</sc> event-related brain potential and functional outcome in persons at clinical high risk for psychosis: A longitudinal study. <i>Psychiatry and Clinical Neurosciences</i> , 2022, 76, 114-121.	1.8	5
2	Serum lipid analysis and isotopic enrichment is suggestive of greater lipogenesis in young long-term cannabis users: A secondary analysis of a case-control study. <i>Lipids</i> , 2022, 57, 125-140.	1.7	3
3	In vivo imaging translocator protein (TSPO) in autism spectrum disorder. <i>Neuropsychopharmacology</i> , 2022, 47, 1421-1427.	5.4	10
4	Identifying Electroencephalography Biomarkers in Individuals at Clinical High Risk for Psychosis in an International Multi-Site Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 828376.	2.6	1
5	P473. Estimating Self-Disturbance in Psychosis and Its Risk States Using Natural Language Processing Analysis of Open-Ended Interviews. <i>Biological Psychiatry</i> , 2022, 91, S280.	1.3	0
6	P556. N400 Event-Related Brain Potential as a Predictor of Symptomatic Outcome in Persons at Clinical High Risk for Psychosis. <i>Biological Psychiatry</i> , 2022, 91, S314.	1.3	0
7	Increased Metaphor Production in Open-Ended Speech Samples of Patients With Prodromal and Developed Schizophrenia Detected with NLP. <i>Biological Psychiatry</i> , 2022, 91, S50.	1.3	1
8	Decreased Gamma Auditory Steady-State Response Is Associated With Impaired Real-World Functioning in Unmedicated Patients at Clinical High Risk for Psychosis. <i>Clinical EEG and Neuroscience</i> , 2021, 52, 400-405.	1.7	7
9	Microglia imaging in methamphetamine use disorder: a positron emission tomography study with the 18 kDa translocator protein radioligand [¹⁸ F]FEPPA. <i>Addiction Biology</i> , 2021, 26, e12876.	2.6	10
10	Fatty acid amide hydrolase is lower in young cannabis users. <i>Addiction Biology</i> , 2021, 26, e12872.	2.6	21
11	Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient-Control Differences. <i>Biological Psychiatry</i> , 2021, 89, e5-e8.	1.3	36
12	Endocannabinoid system in psychotic and mood disorders, a review of human studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 106, 110096.	4.8	29
13	N400 event-related brain potential as an index of real-world and neurocognitive function in patients at clinical high risk for schizophrenia. <i>Microbial Biotechnology</i> , 2021, 15, 68-75.	1.7	6
14	Lower amygdala fatty acid amide hydrolase in violent offenders with antisocial personality disorder: an [¹¹ C]CURB positron emission tomography study. <i>Translational Psychiatry</i> , 2021, 11, 57.	4.8	13
15	Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis. <i>JAMA Psychiatry</i> , 2021, 78, 753.	11.0	74
16	Genetically Predicted Brain C4A Expression Is Associated With TSPO and Hippocampal Morphology. <i>Biological Psychiatry</i> , 2021, 90, 652-660.	1.3	12
17	TSPO Imaging in Psychiatric Disorders. , 2021, , 589-606.		0
18	Relationships between cognitive event-related brain potential measures in patients at clinical high risk for psychosis. <i>Schizophrenia Research</i> , 2020, 226, 84-94.	2.0	31

#	ARTICLE	IF	CITATIONS
19	Concentration, distribution, and influence of aging on the 18â€‰kDa translocator protein in human brain: Implications for brain imaging studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1061-1076.	4.3	13
20	Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studiesâ€”PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice. <i>Schizophrenia Bulletin</i> , 2020, 46, 432-441.	4.3	56
21	Stressâ€”induced cortical dopamine response is altered in subjects at clinical high risk for psychosis using cannabis. <i>Addiction Biology</i> , 2020, 25, e12812.	2.6	9
22	Negative symptoms in the clinical highâ€”risk state for psychosis: Connection with cognition and primacy in impacting functioning. <i>Microbial Biotechnology</i> , 2020, 14, 188-195.	1.7	14
23	Heterogeneity of Striatal Dopamine Function in Schizophrenia: Meta-analysis of Variance. <i>Biological Psychiatry</i> , 2020, 87, 215-224.	1.3	69
24	Investigating Nociceptin/Orphanin Fq (N/OFF) Function via Nop Receptor in Cannabis Users. <i>Biological Psychiatry</i> , 2020, 87, S81.	1.3	0
25	Evidence That Cannabis Exposure, Abuse, and Dependence Are Related to Glutamate Metabolism and Glial Function in the Anterior Cingulate Cortex: A 1H-Magnetic Resonance Spectroscopy Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 764.	2.6	7
26	Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [11C]CURB positron emission tomography study. <i>Neuropsychopharmacology</i> , 2020, 45, 1834-1841.	5.4	23
27	Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis. <i>Biological Psychiatry</i> , 2020, 88, 727-735.	1.3	18
28	Peripheral cytokine and fatty acid associations with neuroinflammation in AD and aMCI patients: An exploratory study. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 679-688.	4.1	19
29	Imaging Nociceptin Receptor Expression in First Episode Psychosis (FEP) Using Positron Emission Tomography With the Novel Ligand [11C] NOP-1A. <i>Biological Psychiatry</i> , 2020, 87, S184.	1.3	0
30	Personality traits in psychosis and psychosis risk linked to TSPO expression: a neuroimmune marker. <i>Personality Neuroscience</i> , 2020, 3, e14.	1.6	1
31	Impaired Prefrontal Cortical Dopamine Release in Schizophrenia During a Cognitive Task: A [11C]FLB 457 Positron Emission Tomography Study. <i>Schizophrenia Bulletin</i> , 2019, 45, 670-679.	4.3	39
32	Prefrontal cortical dopamine release in clinical high risk for psychosis during a cognitive task: a [11C]FLB457 positron emission tomography study. <i>European Neuropsychopharmacology</i> , 2019, 29, 1023-1032.	0.7	2
33	Stress precedes negative symptom exacerbations in clinical high risk and early psychosis: A time-lagged experience sampling study. <i>Schizophrenia Research</i> , 2019, 210, 52-58.	2.0	14
34	Validating mitochondrial electron transport chain content in individuals at clinical high risk for psychosis. <i>Scientific Reports</i> , 2019, 9, 12695.	3.3	6
35	In Vivo Imaging of Translocator Protein in Long-term Cannabis Users. <i>JAMA Psychiatry</i> , 2019, 76, 1305.	11.0	34
36	F134. Association of Neuroinflammation With Duration of Untreated Major Depressive Disorder. <i>Biological Psychiatry</i> , 2019, 85, S265.	1.3	0

#	ARTICLE	IF	CITATIONS
37	Monoamine Oxidase B Total Distribution Volume in the Prefrontal Cortex of Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 634.	11.0	74
38	Money talksâ€”Philanthropists can foster gender and racial equity. <i>EBioMedicine</i> , 2019, 49, 23.	6.1	0
39	N400 event-related brain potential evidence for semantic priming deficits in persons at clinical high risk for psychosis. <i>Schizophrenia Research</i> , 2019, 204, 434-436.	2.0	11
40	A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis. <i>European Neuropsychopharmacology</i> , 2019, 29, 330-348.	0.7	33
41	Preliminary data indicating a connection between stress-induced prefrontal dopamine release and hippocampal TSPO expression in the psychosis spectrum. <i>Schizophrenia Research</i> , 2019, 213, 80-86.	2.0	8
42	GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 111-119.	2.4	26
43	Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data. <i>Biological Psychiatry</i> , 2018, 84, 433-442.	1.3	103
44	Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. <i>Lancet Psychiatry</i> , 2018, 5, 339-347.	7.4	192
45	Mitochondrial function in individuals at clinical high risk for psychosis. <i>Scientific Reports</i> , 2018, 8, 6216.	3.3	23
46	Interaction between TSPOâ€”a neuroimmune markerâ€”and redox status in clinical high risk for psychosis: a PETâ€”MRS study. <i>Neuropsychopharmacology</i> , 2018, 43, 1700-1705.	5.4	22
47	A systematic review of the role of the nociceptin receptor system in stress, cognition, and reward: relevance to schizophrenia. <i>Translational Psychiatry</i> , 2018, 8, 38.	4.8	22
48	Event-Related Potentials in the Clinical High-Risk (CHR) State for Psychosis: A Systematic Review. <i>Clinical EEG and Neuroscience</i> , 2018, 49, 215-225.	1.7	36
49	Nigral Stress-Induced Dopamine Release in Clinical High Risk and Antipsychotic-Naïve Schizophrenia. <i>Schizophrenia Bulletin</i> , 2018, 44, 542-551.	4.3	26
50	Molecular imaging of neuroinflammation in Alzheimer's disease and mild cognitive impairment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 80, 123-131.	4.8	76
51	Glutathione, the Major Redox Regulator, in the Prefrontal Cortex of Individuals at Clinical High Risk for Psychosis. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 311-318.	2.1	28
52	Imaging microglial activation and amyloid burden in amnesic mild cognitive impairment. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 1885-1895.	4.3	29
53	Cortical stress regulation is disrupted in schizophrenia but not in clinical high risk for psychosis. <i>Brain</i> , 2018, 141, 2213-2224.	7.6	32
54	Normal glutathione levels in autopsied brain of chronic users of heroin and of cocaine. <i>Drug and Alcohol Dependence</i> , 2018, 190, 20-28.	3.2	9

#	ARTICLE	IF	CITATIONS
55	Maladaptive personality traits in patients identified at lower-risk and higher-risk for psychosis. <i>Psychiatry Research</i> , 2018, 268, 348-353.	3.3	11
56	F209. Semantic Processing Abnormalities and Their Relationship to Symptoms in Persons at Clinical High Risk for Schizophrenia: An Event-Related Brain Potential Study. <i>Biological Psychiatry</i> , 2018, 83, S320.	1.3	1
57	Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis. <i>Neuropsychopharmacology</i> , 2018, 43, 2249-2255.	5.4	33
58	TSPO expression and brain structure in the psychosis spectrum. <i>Brain, Behavior, and Immunity</i> , 2018, 74, 79-85.	4.1	17
59	Voxel level quantification of [11C]CURB, a radioligand for Fatty Acid Amide Hydrolase, using high resolution positron emission tomography. <i>PLoS ONE</i> , 2018, 13, e0192410.	2.5	3
60	Mechanisms contributing to cognitive deficits in cannabis users. <i>Neuropharmacology</i> , 2017, 124, 84-88.	4.1	24
61	Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder. <i>JAMA Psychiatry</i> , 2017, 74, 833.	11.0	132
62	Evaluation of a novel radiotracer for positron emission tomography imaging of reactive oxygen species in the central nervous system. <i>Nuclear Medicine and Biology</i> , 2017, 53, 14-20.	0.6	25
63	Imaging Microglial Activation in Individuals at Clinical High Risk for Psychosis: an In Vivo PET Study with [18F]FEPPA. <i>Neuropsychopharmacology</i> , 2017, 42, 2474-2481.	5.4	47
64	Corticotropin-releasing hormone and dopamine release in healthy individuals. <i>Psychoneuroendocrinology</i> , 2017, 76, 192-196.	2.7	20
65	191. Semantic Priming Deficits in Persons at Clinical High Risk for Schizophrenia: Evidence from Event-Related Brain Potentials. <i>Biological Psychiatry</i> , 2017, 81, S79.	1.3	0
66	Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies. <i>International Review of Psychiatry</i> , 2017, 29, 555-566.	2.8	6
67	Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [¹⁸ F]FEPPA. <i>American Journal of Psychiatry</i> , 2017, 174, 118-124.	7.2	103
68	Inhibition of fatty acid amide hydrolase by BIA 10-2474 in rat brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3635-3639.	4.3	10
69	Towards an Integrated View of Early Molecular Changes Underlying Vulnerability to Social Stress in Psychosis. <i>Modern Problems of Pharmacopsychiatry</i> , 2017, 31, 96-106.	2.5	5
70	Stress Response in Cannabis Users and Psychosis. , 2017, , 278-287.		0
71	Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw181.	4.3	44
72	Neuroinflammation and Oxidative Stress in Psychosis and Psychosis Risk. <i>International Journal of Molecular Sciences</i> , 2017, 18, 651.	4.1	124

#	ARTICLE	IF	CITATIONS
73	Feasibility study of TSPO quantification with [18F]FEPPA using population-based input function. PLoS ONE, 2017, 12, e0177785.	2.5	20
74	Disrupted Nodal and Hub Organization Account for Brain Network Abnormalities in Parkinson's Disease. Frontiers in Aging Neuroscience, 2016, 8, 259.	3.4	53
75	Imaging neuroinflammation in schizophrenia and depression with PET. European Neuropsychopharmacology, 2016, 26, S134.	0.7	0
76	Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB. Biological Psychiatry, 2016, 80, 691-701.	1.3	53
77	Cerebrovascular and microglial states are not altered by functional neuroinflammatory gene variant. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 819-830.	4.3	5
78	Amyloid deposition in semantic dementia: a positron emission tomography study. International Journal of Geriatric Psychiatry, 2016, 31, 1064-1074.	2.7	9
79	Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Molecular Psychiatry, 2016, 21, 1009-1026.	7.9	272
80	Social Stress and Psychosis Risk: Common Neurochemical Substrates?. Neuropsychopharmacology, 2016, 41, 666-674.	5.4	79
81	Human Kinetic Modeling of the 5HT ₆ PET Radioligand [¹¹ C]-GSK215083 and Its Utility for Determining Occupancy at Both 5HT ₆ and 5HT _{2A} Receptors by SB742457 as a Potential Therapeutic Mechanism of Action in Alzheimer Disease. Journal of Nuclear Medicine, 2015, 56, 1901-1909.	5.0	24
82	High stress, low resilience in people at clinical high risk for psychosis: Should we consider a strengths-based approach?. Canadian Psychology, 2015, 56, 332-347.	2.1	2
83	Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. PLoS ONE, 2015, 10, e0138721.	2.5	95
84	Imaging Neuroinflammation in Gray and White Matter in Schizophrenia: An In-Vivo PET Study With [18F]-FEPPA. Schizophrenia Bulletin, 2015, 41, 85-93.	4.3	158
85	The Fatty Acid Amide Hydrolase C385A Variant Affects Brain Binding of the Positron Emission Tomography Tracer [¹¹ C]CURB. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1237-1240.	4.3	58
86	Blocking of Fatty Acid Amide Hydrolase Activity with PF-04457845 in Human Brain: A Positron Emission Tomography Study with the Novel Radioligand [¹¹ C]CURB. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1827-1835.	4.3	28
87	In-vivo imaging of grey and white matter neuroinflammation in Alzheimer's disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA. Molecular Psychiatry, 2015, 20, 1579-1587.	7.9	101
88	Role of Translocator Protein Density, a Marker of Neuroinflammation, in the Brain During Major Depressive Episodes. JAMA Psychiatry, 2015, 72, 268.	11.0	700
89	Imaging changes associated with cognitive abnormalities in Parkinson's disease. Brain Structure and Function, 2015, 220, 2249-2261.	2.3	41
90	Kinetic Modeling of the Monoamine Oxidase B Radioligand [¹¹ C]SL25.1188 in Human Brain with High-Resolution Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 883-889.	4.3	83

#	ARTICLE	IF	CITATIONS
91	Quantitative imaging of neuroinflammation in human white matter: A positron emission tomography study with translocator protein 18 kDa radioligand, [¹⁸ F]â€FEPPA. Synapse, 2014, 68, 536-547.	1.2	17
92	Whole-Body Radiation Dosimetry of ¹¹ C-Carbonyl-URB694: A PET Tracer for Fatty Acid Amide Hydrolase. Journal of Nuclear Medicine, 2014, 55, 1993-1997.	5.0	15
93	Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18kDa (TSPO) radioligand, [18F]-FEPPA. NeuroImage, 2014, 84, 868-875.	4.2	56
94	PIB-Positive PET in Individuals with Early- but Not Late-Onset Frontotemporal Dementia. American Journal of Geriatric Psychiatry, 2014, 22, S81-S82.	1.2	0
95	Stress-Induced Dopamine Response in Subjects at Clinical High Risk for Schizophrenia with and without Concurrent Cannabis Use. Neuropsychopharmacology, 2014, 39, 1479-1489.	5.4	86
96	Image Derived Input Function for [18F]-FEPPA: Application to Quantify Translocator Protein (18 kDa) in the Human Brain. PLoS ONE, 2014, 9, e115768.	2.5	11
97	Whole Body Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, [18F]-FEPPA, to Image Translocator Protein (18kDa). Molecular Imaging and Biology, 2013, 15, 353-359.	2.6	23
98	Dopamine Response to Psychosocial Stress in Chronic Cannabis Users: A PET Study With [11C]-(+)-PHNO. Neuropsychopharmacology, 2013, 38, 673-682.	5.4	45
99	Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naïve patients and healthy controls while performing a cognitive task. Journal of Psychiatry and Neuroscience, 2013, 38, 98-106.	2.4	36
100	Mapping Human Brain Fatty Acid Amide Hydrolase Activity with PET. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 407-414.	4.3	65
101	Voxel-Based Imaging of Translocator Protein 18Kda (TSPO) in High-Resolution PET. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 348-350.	4.3	10
102	Translocator Protein (18kDa) Polymorphism (rs6971) Explains <i>in-vivo</i> Brain Binding Affinity of the PET Radioligand [¹⁸ F]-FEPPA. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 968-972.	4.3	131
103	Whole-Body Distribution and Radiation Dosimetry of ¹¹ C-(+)-PHNO, a D _{2/3} Agonist Ligand. Journal of Nuclear Medicine, 2012, 53, 1802-1806.	5.0	1
104	Increased Stress-Induced Dopamine Release in Psychosis. Biological Psychiatry, 2012, 71, 561-567.	1.3	222
105	Biodistribution and Radiation Dosimetry of the Serotonin 5-HT ₆ Ligand [11C]GSK215083 Determined from Human Whole-Body PET. Molecular Imaging and Biology, 2012, 14, 517-521.	2.6	7
106	Dopamine response to psychosocial stress in humans and its relationship to individual differences in personality traits. Journal of Psychiatric Research, 2012, 46, 890-897.	3.1	26
107	Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naïve patients with schizophrenia using [11C]-(+)-PHNO. Schizophrenia Research, 2011, 131, 63-68.	2.0	78
108	The four dimensions: a model for the social aetiology of psychosis. British Journal of Psychiatry, 2011, 199, 11-14.	2.8	37

#	ARTICLE	IF	CITATIONS
109	Quantitation of Translocator Protein Binding in Human Brain with the Novel Radioligand [¹⁸ F]-FEPPA and Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 1807-1816.	4.3	98
110	Side Effects Profile in Humans of ¹¹ C-(+)-PHNO, a Dopamine D _{2/3} Agonist Ligand for PET. <i>Journal of Nuclear Medicine</i> , 2010, 51, 496-497.	5.0	19
111	Advances in PET analyses of stress and dopamine. <i>Neuropsychopharmacology</i> , 2010, 35, 348-349.	5.4	8
112	The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors. <i>Archives of General Psychiatry</i> , 2009, 66, 606.	12.3	97
113	The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 715.	2.1	52
114	The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [¹¹ C]-(+)-PHNO PET Study. <i>Neuropsychopharmacology</i> , 2009, 34, 1078-1086.	5.4	109
115	Correspondences between theory of mind, jumping to conclusions, neuropsychological measures and the symptoms of schizophrenia. <i>Psychiatry Research</i> , 2009, 170, 119-123.	3.3	72
116	Neuroimaging Correlates of Apathy and Depression in Alzheimer's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2009, 21, 259-265.	1.8	103
117	Brain region binding of the D2/3 agonist [¹¹ C]-(+)-PHNO and the D2/3 antagonist [¹¹ C]raclopride in healthy humans. <i>Human Brain Mapping</i> , 2008, 29, 400-410.	3.6	95
118	"Jumping to conclusions" and delusions in psychosis: Relationship and response to treatment. <i>Schizophrenia Research</i> , 2008, 98, 225-231.	2.0	97
119	Attribution style as a factor in psychosis and symptom resolution. <i>Schizophrenia Research</i> , 2008, 104, 220-227.	2.0	30
120	Depression in Alzheimer's disease: Phenomenology, clinical correlates and treatment. <i>International Review of Psychiatry</i> , 2008, 20, 382-388.	2.8	90
121	Antidepressant therapy in post-stroke depression. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1291-1298.	1.8	55
122	Adverse Subjective Experience With Antipsychotics and Its Relationship to Striatal and Extrastriatal D ₂ Receptors: a PET Study in Schizophrenia. <i>American Journal of Psychiatry</i> , 2007, 164, 630-637.	7.2	141
123	Differential Effects of Aripiprazole on D ₂ , 5-HT ₂ , and 5-HT _{1A} Receptor Occupancy in Patients With Schizophrenia: A Triple Tracer PET Study. <i>American Journal of Psychiatry</i> , 2007, 164, 1411-1417.	7.2	235
124	The effect of antipsychotic treatment on Theory of Mind. <i>Psychological Medicine</i> , 2007, 37, 595.	4.5	64
125	Neuropsychological Correlates of Normal Variation in Emotional Response to Visual Stimuli. <i>Journal of Nervous and Mental Disease</i> , 2007, 195, 112-118.	1.0	6
126	Epidemiology and Management of Apathy in Patients with Alzheimer's Disease. <i>Drugs and Aging</i> , 2007, 24, 547-554.	2.7	14

#	ARTICLE	IF	CITATIONS
127	Insight and danger in Alzheimer's disease. <i>European Journal of Neurology</i> , 2007, 14, 455-460.	3.3	114
128	Depression in Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 887-895.	2.8	58
129	A prospective longitudinal study of apathy in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 8-11.	1.9	270
130	Phenomenology and Clinical Correlates of Delusions in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 573-581.	1.2	41
131	The selective effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2006, 88, 111-118.	2.0	52
132	Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. <i>Journal of Neurochemistry</i> , 2006, 97, 1089-1103.	3.9	145
133	How antipsychotics work: From receptors to reality. <i>NeuroRx</i> , 2006, 3, 10-21.	6.0	77
134	A diagnostic formulation for anosognosia in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 719-725.	1.9	190
135	The prevalence, clinical correlates and treatment of apathy in Alzheimer's disease. <i>European Journal of Psychiatry</i> , 2006, 20, .	1.3	29
136	The Construct of Minor and Major Depression in Alzheimer's Disease. <i>American Journal of Psychiatry</i> , 2005, 162, 2086-2093.	7.2	230
137	On the overlap between apathy and depression in dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1070-1074.	1.9	204
138	Specificity of Symptoms of Depression in Alzheimer Disease: A Longitudinal Analysis. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 802-807.	1.2	30
139	How antipsychotics work: The patients' perspective. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 859-864.	4.8	30
140	From dopamine to salience to psychosis: linking biology, pharmacology and phenomenology of psychosis. <i>Schizophrenia Research</i> , 2005, 79, 59-68.	2.0	433
141	Specificity of Symptoms of Depression in Alzheimer Disease: A Longitudinal Analysis. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 802-807.	1.2	23
142	White matter hyperintensities are significantly associated with cortical atrophy in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 822-827.	1.9	146
143	Management of post-stroke depression. , 0, , 107-115.		0